Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Botulism

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Laparoscopic splenic flexure resection for early colorectal cancer, transanal specimen extraction and intracorporeal handsewn anastomosis: a video vignette.

Techniques in coloproctology·2021

Same author

ASO Author Reflections: Thoraco-Abdominal Approach with Phrenotomy for Large Liver Tumor in Close Contact with the Vena Cava and the Hepatocaval Confluence.

Annals of surgical oncology·2021

Same author

Extended Right Hepatectomy for Hepatocellular Carcinoma.

Annals of surgical oncology·2021

Same author

Assessment of severity of acute pancreatitis in a Sars-CoV-2 pandemia.

The British journal of surgery·2020

Same author

The new retained foreign body! Case report and review of the literature on retained foreign bodies in laparoscopic bariatric surgery.

European review for medical and pharmacological sciences·2012

Same author

Influence of carcass weight on instrumental and sensory lamb meat quality in intensive production systems.

Meat science·2011

Search research articles

Related Experiment Video

Updated: May 31, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Treating benign prostatic hyperplasia with botulinum neurotoxin.

G Brisinda¹, S Vanella, G Marniga

¹Department of Surgery, Catholic School of Medicine, University Hospital "Agostino Gemelli", Largo Agostino Gemelli 8, 00168 Rome, Italy. gbrisin@tin.it

Current Medicinal Chemistry

|July 16, 2011

Summary

Botulinum toxin type A (BoNT-A) shows promise as an alternative treatment for benign prostatic hyperplasia (BPH). This approach may alleviate lower urinary tract symptoms (LUTS) by targeting prostate contraction and sensation.

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

Related Experiment Videos

Last Updated: May 31, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

Area of Science:

Urology
Pharmacology
Interventional Medicine

Background:

Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, causing lower urinary tract symptoms (LUTS).
Current medical and surgical treatments for BPH have limitations in efficacy and potential complications.
Botulinum toxin (BoNT) is increasingly utilized for various medical conditions, including those involving smooth muscle and nerve function.

Purpose of the Study:

To explore the potential of Botulinum toxin type A (BoNT-A) as an alternative therapeutic option for benign prostatic hyperplasia (BPH).
To evaluate the feasibility of using BoNT-A to manage LUTS associated with BPH.

Main Methods:

Review of clinical experience with BoNT-A injections in patients with BPH.
Investigation of BoNT-A's mechanism of action on autonomic efferent and afferent pathways in the prostate.

Main Results:

BoNT-A may offer an alternative to traditional BPH treatments by inhibiting prostate contraction and modulating sensory input.
Potential advantages include localized effects, rare systemic side effects, and adjustable relaxation levels.

Conclusions:

Botulinum toxin type A presents a potential novel treatment strategy for benign prostatic hyperplasia.
Further clinical evaluation is warranted to establish the efficacy and safety of BoNT-A for BPH management.